Dr. McKay Discusses Advances in the Treatment of Metastatic RCC

Rana R. McKay, MD
Published: Thursday, Jan 04, 2018



Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses advances in the treatment of metastatic renal cell carcinoma (RCC).

One of the most influential studies over the past few years has been the CheckMate-025 study in patients with metastatic clear cell RCC, says McKay. This was the first time that a second-line treatment was shown to improve overall survival in this population.

Studies with cabozantinib (Cabometyx), ipilimumab (Yervoy) plus nivolumab (Opdivo), and sunitinib (Sutent) have also enriched the treatment landscape of metastatic RCC, McKay adds.
 


Rana R. McKay, MD, medical oncologist, assistant professor, Moores Cancer Center at the University of California, San Diego, discusses advances in the treatment of metastatic renal cell carcinoma (RCC).

One of the most influential studies over the past few years has been the CheckMate-025 study in patients with metastatic clear cell RCC, says McKay. This was the first time that a second-line treatment was shown to improve overall survival in this population.

Studies with cabozantinib (Cabometyx), ipilimumab (Yervoy) plus nivolumab (Opdivo), and sunitinib (Sutent) have also enriched the treatment landscape of metastatic RCC, McKay adds.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x